Department of Obstetrics and Gynecology, University of Health Sciences, Gaziosmanpasa Training and Research Hospital, Istanbul, Turkey.
Department of Obstetrics and Gynecology, Ordu University Training and Research Hospital, Ordu, Turkey.
Medicine (Baltimore). 2023 May 19;102(20):e33824. doi: 10.1097/MD.0000000000033824.
To search whether or not the severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine affects the fertility of women at the 6th months by using AMH, which is an ovarian reserve test. Our study, designed as a prospective case-control study, included 104 women who presented to the GOP EAH obstetrics and gynecology outpatient clinic in January and February 2022. The study group included 74 women who presented to the outpatient clinic and planned to be vaccinated and 30 women who refused to be vaccinated as the control group. Anti-COVID-19 antibody levels in all participants were checked before participation in the study, and participants who were positive were excluded from the study. Blood was taken from the participants in both control and study groups to evaluate their AMH levels before the 2 doses of vaccination. After 2 doses of the vaccine, they were called for follow-up, and serological tests were performed to check whether they were positive for anti-COVID-19 antibodies. Participants in both groups were referred for follow-up after 6 months, samples were taken again for AMH, and the data were recorded. The mean age of the study group was 27.6 ± 5.3 years, and the mean age of the control group was 28.65 ± 5.25 years (P = .298). There was no statistically significant difference between the vaccinated and nonvaccinated groups in terms of AMH levels measured at the 6th month (P = .970). When the vaccinated group was compared in terms of AMH values at the first visit before vaccination and at the 6th month after vaccination, no statistically significant difference was found between them (p:0.127) mRNA vaccination to protect against SARS-CoV-2 does not adversely affect ovarian reserve, which is an indirect indicator of fertility. mRNA vaccines continue to be the most important method of protection against epidemics. Carefully and accurately informing women who are hesitant to get vaccinated is of great importance for the success of the fight against the epidemic.
通过使用抗苗勒管激素（AMH）——一种卵巢储备测试，来研究新型冠状病毒-2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗是否会在 6 个月内对女性生育能力造成影响。
我们的研究设计为前瞻性病例对照研究，共纳入了 2022 年 1 月和 2 月在 GOP EAH 妇产科门诊就诊的 104 名女性。研究组包括 74 名因计划接种疫苗而就诊的女性和 30 名拒绝接种疫苗的女性作为对照组。所有参与者在参与研究前均检查了抗 COVID-19 抗体水平，阳性者被排除在研究之外。采集对照组和研究组所有参与者的血液，评估他们在接种 2 剂疫苗前的 AMH 水平。接种 2 剂疫苗后，他们被随访，并进行血清学检查，以检查他们的抗 COVID-19 抗体是否呈阳性。接种疫苗的两组患者在 6 个月后进行了随访，再次采集样本进行 AMH 检查，并记录数据。研究组的平均年龄为 27.6±5.3 岁，对照组的平均年龄为 28.65±5.25 岁（P=0.298）。在接种疫苗的患者中，接种疫苗和未接种疫苗的患者在第 6 个月时测量的 AMH 水平没有统计学差异（P=0.970）。在接种疫苗的患者中，比较他们在接种疫苗前第一次就诊和接种疫苗后第 6 个月的 AMH 值时，两者之间没有统计学差异（p：0.127）。
mRNA 疫苗接种预防 SARS-CoV-2 不会对卵巢储备产生不利影响，卵巢储备是生育能力的间接指标。mRNA 疫苗仍然是预防传染病的最重要方法。仔细、准确地告知犹豫不决的女性接种疫苗的重要性，对抗击疫情的成功至关重要。
